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Blood biomarkers for mild traumatic
brain injury: a selective review of unresolved
issues
Daniel B. Hier1* , Tayo Obafemi-Ajayi2 , Matthew S. Thimgan3 , Gayla R. Olbricht4 , Sima Azizi1 ,
Blaine Allen1 , Bassam A. Hadi5 and Donald C. Wunsch II1,6
Abstract
Background: The use of blood biomarkers after mild traumatic brain injury (mTBI) has been widely studied. We have
identified eight unresolved issues related to the use of five commonly investigated blood biomarkers: neurofilament
light chain, ubiquitin carboxy-terminal hydrolase-L1, tau, S100B, and glial acidic fibrillary protein. We conducted a
focused literature review of unresolved issues in three areas: mode of entry into and exit from the blood, kinetics of
blood biomarkers in the blood, and predictive capacity of the blood biomarkers after mTBI.
Findings: Although a disruption of the blood brain barrier has been demonstrated in mild and severe traumatic
brain injury, biomarkers can enter the blood through pathways that do not require a breach in this barrier. A definitive
accounting for the pathways that biomarkers follow from the brain to the blood after mTBI has not been performed.
Although preliminary investigations of blood biomarkers kinetics after TBI are available, our current knowledge is
incomplete and definitive studies are needed. Optimal sampling times for biomarkers after mTBI have not been
established. Kinetic models of blood biomarkers can be informative, but more precise estimates of kinetic parameters
are needed. Confounding factors for blood biomarker levels have been identified, but corrections for these factors are
not routinely made. Little evidence has emerged to date to suggest that blood biomarker levels correlate with clinical
measures of mTBI severity. The significance of elevated biomarker levels thirty or more days following mTBI is
uncertain. Blood biomarkers have shown a modest but not definitive ability to distinguish concussed from
non-concussed subjects, to detect sub-concussive hits to the head, and to predict recovery from mTBI. Blood
biomarkers have performed best at distinguishing CT scan positive from CT scan negative subjects after mTBI.
Keywords: NF-L, UCH-L1, GFAP, Mild traumatic brain injury, Kinetics, S100B, Blood biomarkers, Tau, Concussion,
Return to sport, CT scan

Background
Mild traumatic brain injury (mTBI), also known as concussion, has been defined as a minor head injury with
a Glasgow Coma Scale score of 13 to 15. Loss of consciousness and post traumatic amnesia occur variably.
The CT scan and MRI may be normal or show minor
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1

abnormalities. A variety of protein macromolecules and
smaller molecules detectable in the blood and cerebrospinal fluid have been investigated as biomarkers for
mTBI [1–13]. This review focuses on five of the most
commonly studied markers for mTBI: glial fibrillary acidic
protein (GFAP), neurofilament light chain protein (NFL), ubiquitin C-terminal hydrolase-L1 (UCH-L1), tau, and
S100B. Since these five protein biomarkers have been
extensively reviewed, we briefly highlight some of their
important features as a context for this review. Glial fibrillary acidic protein, a 50 kDa protein, is the primary
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component of intermediate filaments in astrocytes [5].
GFAP monomers homo-polymerize to form the intermediate filament cytoskeleton of astrocytes [14, 15]. GFAP is
upregulated during astrogliosis and is likely released from
astrocytes after traumatic brain injury [6]. Levels of GFAP
are elevated in both the cerebrospinal fluid and blood after
TBI [16, 17]. Neurofilament protein comes in three forms:
a 200 kDa heavy chain (NF-H), a 150 kDa medium-chain
(NF-M), and a 68 kDa light chain (NF-L). The backbones
of 10 nm diameter neurofilaments in neurons are assembled by the polymerization of neurofilament light chains
and the side arms are made from neurofilament medium
and heavy chains [18, 19]. Mature neurofilaments provide
a stable framework within the axons of neurons. NF-L
protein has a slow turnover in axons with an estimated
intracellular half-life of 3 weeks [18, 20]. NF-L levels are
increased in both the blood and cerebrospinal fluid after
TBI [21]. Ubiquitin C-terminal hydrolase-L1 is a 25 kDa
enzyme that is highly expressed in neurons. It is involved
in ubiquitination and de-ubiquitination of proteins allocated for catabolism. Blood and cerebrospinal fluid levels
of UCH-L1 are elevated after TBI [22].
Tau is a protein involved in the stabilization of microtubules in the axons of neurons in both the central and
peripheral nervous system. In the central nervous system, tau has six isoforms (A-F) with molecular weights
ranging from 33 kDa to 46 kDa [23]. Tau has been measured after TBI in a variety of forms, including cleaved-tau
(tau-C), phosphorylated-tau (tau-P), and total tau (tau-T).
Although elevated tau levels indicate neuronal injury, tau
is released into the interstitial fluid by healthy neurons
[24]. Intracellular turnover of tau is slow, with an estimated half-life of 19-30 days [24]. Tau is elevated in the
plasma and cerebrospinal fluid after TBI [25]. S100B (formerly S100-β) is a low-molecular weight 10 kDa calciumbinding protein expressed in glia and Schwann cells. Blood
levels of S100B may be elevated after trauma without head
injury [7]. Immediately after TBI, extracranial sources of
S100B may be significant [26]. Elimination of S100B from
the blood is rapid with a half-life between 0.5 and 2 hrs
[26–28]. After TBI, levels in the cerebrospinal fluid may
be up to 100 times higher than serum levels [26].
Selection of issues for focused review

Despite much investigation of blood biomarkers in the
settings of mild, moderate, and severe brain injury, some
issues regarding their use remain unresolved [4–12].
McDonald et al. [13] have recently emphasized that
known unknowns exist for the use of blood biomarkers
for mTBI including the mechanism by which biomarkers gain entry to the blood (via blood brain barrier or
glymphatic system), biomarker kinetics including rates of
absorption and elimination, and analytic issues (including
obtaining, processing, and analyzing blood samples). This
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review focuses on eight unresolved issues related to the
use of blood biomarkers to diagnose and manage mTBI
1. How do biomarkers enter and exit the blood?
2. What are the kinetics of blood biomarkers?
3. What is the optimal sampling time for blood
biomarkers?
4. How long do the blood biomarker levels remain
elevated?
5. What are the confounding factors for blood
biomarker levels?
6. Can blood biomarkers differentiate between subjects
with concussions or sub-concussive hits to the head
from healthy controls?
7. Can blood biomarkers predict CT scan positivity?
8. Can blood biomarkers predict outcome or severity of
mTBI?
This list of unresolved issues is selective and is not comprehensive. Most of the literature discussed in this paper
stems from the intersection of the searches in Ovid MEDLINE and Epub Ahead of Print (1946 to February 5, 2021)
for the keyword traumatic brain injuries (15,999) and
the search terms UCH-L1 OR GFAP OR tau proteins
OR S100 proteins OR neurofilament proteins (54,631)
which yielded 406 articles. We added 202 articles with
the search terms glymphatic system OR periarterial
drainage. We added 195 articles from ad hoc searches.
We reviewed the titles and abstracts of 803 full-text publications to select the 140 articles retained for this review.

Review findings
How do biomarkers enter and exit the blood after mTBI?

After mTBI, axonal shearing and cellular disruption cause
the release of biomarkers from neurons and astrocytes
[1, 8]. NF-L, UCH-L1, and tau are released from neurons; GFAP and S100B are released from astrocytes [8].
These biomarkers are released into the surrounding interstitial fluid. A dose-response relationship for the release of
biomarkers has not been established, i.e. there no proven
linear or non-linear relationship between the amount of
biomarker released into the interstitial fluid and the force
of the impact to the head. Bui et al. [29] examined the
modality of blood biomarker levels after mTBI in a dataset
of concussed athletes from the Concussion Assessment,
Research, and Education Consortium Study (CARE) study
[30, 31]. (Data is available via the Federal Interagency
Traumatic Brain Injury Research (FITBIR) [32] repository to approved investigators.). Based on a test for
modality, we found that biomarker levels after concussion
were multi-modal rather that than uni-modal [29]. When
subjects were clustered by biomarker trajectory after
mTBI, some clusters showed a robust rise in biomarker
levels while others showed a modest or minimal rise in
biomarker levels [29] (Fig. 1).
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Fig. 1 Cluster trajectories for NF-L biomarker for concussed contact sport subjects formed two clusters C1 and C2. C1 (red line) showed a robust rise
in NF-L after concussion whereas C2 (purple line) showed a modest elevation in NF-L not much different from the non-contact sport concussed,
contact sport controls, and not-contact sport controls. C1 and C2 differed at all time points (p <0.05). Reproduced from [29] with permission.
Original data from CARE study [30]

With a volume of approximately 1200 ml, the human
brain is tightly packed with cellular elements (neurons, astrocytes, oligodendrocytes and their myelin, and
microglia). About 20% of the brain is extracellular space
[33]; filled with an extracellular matrix and approximately
120 ml of interstitial fluid. The interstitial fluid brings
nutrients to the neurons and glia of the brain and removes
waste products. Proteins move through the interstitial
fluid by diffusion or more rapidly by convection [33–35].
The extracellular space is highly confined with narrow
passages that are 38-64 nm diameter [33]. Given the large
size of some protein biomarkers (Table 1), these tight passages can slow the diffusion of biomarkers. Movement in
these tight passages is by hindered diffusion and larger
molecules are slowed more than smaller molecules [33,
37]
After mTBI, biomarkers can potential diffuse through
the extracellular space of the brain to penetrating blood
vessels and enter the blood if the blood brain barrier is
disrupted. Disruption of the blood brain barrier occurs
with moderate or severe brain injury in about 40% of the
cases [38, 39]. It is less certain whether disruption of the
blood brain barrier occurs routinely with mild traumatic
brain injury [13]. Using meningeal enhancement on MRI
as a surrogate for disruption of the blood brain barrier, it
has been suggested that transient disruption of the blood
brain occurs in about 50% of the cases of mTBI [40]. It

is possible that some biomarkers reach the blood by diffusing to the vessel walls in the brain and crossing the
blood brain barrier directly [13]. Nonetheless, given that
biomarkers can be detected in the blood of normal individuals with intact blood brain barriers and that many
subjects with mTBI do not have a disruption of the blood
brain barrier, it is likely that other routes account for some
entry of biomarker into the blood after mTBI.
After TBI, levels of biomarkers in the cerebrospinal fluid
rise rapidly, suggesting that these biomarkers have easy
access to the cerebrospinal fluid from the interstitial fluid.
Biomarkers can reach the cerebrospinal fluid by transependymal flow into the ventricles or trans-pial flow into
the subarachnoid space [35]. Once in the cerebrospinal
fluid, biomarkers circulate by convection or diffusion. The
traditional model of the cerebrospinal fluid circulation
[41, 42] involves the production of cerebrospinal fluid by
the choroid plexus, passage through the aqueduct to the
fourth ventricle and then flow outward to the convexities
of the brain and to the lumbar subarachnoid space [43].
The cerebrospinal fluid volume (150 ml) turns over four
times per day [43]. Some cerebrospinal fluid is absorbed
into the blood at the arachnoid granulations along the
superior sagittal sinus. It is uncertain to what extent
protein biomarkers can traverse the narrow passages of
the arachnoid granulations to leave the cerebrospinal
fluid and enter the blood. Most cerebrospinal fluid exits
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Table 1 Some Properties of Proteins Investigated as Biomarkers for mTBI
Biomarker

MW†

Residues†

Role

Localization

Cell

S100B

10.7

92

regulatory

cytoplasm

astrocyte

UCH-L1

24.8

223

enzymatic

cytoplasm

neuron

tau isoform A§

32.9

316

structural

axon

neuron

tau isoform F§

45.8

441

structural

axon

neuron

GFAP

49.9

543

structural

cytoplasm

astrocyte

NF-L

61.5

304

structural

axon

neuron

§

Human CNS tau has 6 isoforms A-F [23].
†
Molecular weight (MW) in kDa, Residues is the number of amino acids [36]

the cerebrospinal fluid compartment via lymphatic channels [44] at the cribriform plate (olfactory nerve), along
other cranial nerve roots and along spinal roots. Radioactively labeled biomarker injected into the lateral ventricles
appears in the lymph nodes within 6-8 hrs [44, 45], supporting the importance of these lymphatic routes for
the absorption of cerebrospinal fluid and clearance of
biomarkers from the cerebrospinal fluid.
It has been recognized for more than 25 years that
radioactively labeled albumin injected into the interstitial
fluid of the brain can be recovered from cervical lymph
nodes draining the head [44]. Since albumin is larger in
size than the protein biomarkers for TBI, it is likely that
biomarkers released into the interstitial fluid have access
to the blood through the lymphatic system. Two competing hypotheses have emerged as to the route of proteins
from the interstitial fluid of the brain to the lymphatic
system. One group has proposed that proteins and other
waste products reach the lymph system through an intramural peri-arterial drainage system [46–50]. This model
emphasizes intramural periarterial routes for drainage of
protein molecules from the interstitial fluid. A second
group [34, 51–57] has proposed a glymphatic system for
removal of waste products from the interstitial fluid and
their drainage into the lymphatic system. In their model,
a convective flow of fluid through the interstitial space
between small arteries and veins fosters drainage of waste
and proteins into a para-venous space to the lymphatic
system. The exact mechanism and precise anatomy by
which biomarkers exit the interstitial fluid and drain into
the lymph system and back to the blood remains unsettled
[58, 59]. The relative contributions to blood biomarkers
from biomarker transiting directly across the blood brain
barrier versus transiting to the blood via the lymphatics is
also unsettled [13].
Once in the blood, biomarkers must have a mode of
exit. Little is known with certainty about the mode of
elimination of biomarkers from the blood. Elimination
could occur by redistribution to other compartments,
renal excretion, hepatic metabolism, or intravascular proteolysis [13]. Dadas et al. ([60–62] have suggested that

elimination of biomarkers after TBI is likely renal and
that the rate of elimination is inversely proportional to
biomarker molecular weight, with smaller biomarkers
eliminated more rapidly than larger ones (e.g. S100B is
eliminated more quickly than GFAP). An inverse relationship between renal elimination and molecular weight up
to molecules as large as 70 kDa is known [63].
What are the kinetics of blood biomarkers after mTBI?

When the blood levels of biomarkers are sampled repeatedly after a mTBI, time-concentration curves can be
created [64]. The descriptive kinetic parameters time to
maximum concentration (Tmax ), maximum concentration
(Cmax ), and half-life (t 1 ) are useful for describing these
2
curves (Fig. 2). A limited number of formal kinetic studies of blood biomarkers after TBI are available [22, 60, 62,
65, 66]. Published time-concentration curves allow estimates of Tmax and half-life for the commonly investigated
blood biomarkers (Table 2) [1, 9, 11, 12, 17, 65]. Estimates
of Tmax and half-life are notably uncertain for NF-L due
to a paucity of kinetic studies at longer time intervals after
mTBI (Table 2). Azizi et al. [74] have modeled the blood
levels of biomarkers after mTBI as a one-compartment
pharmacokinetic model. In a one-compartment pharmacokinetic model, two first-order rate constants ka (the
absorption rate constant) and ke (the elimination rate constant) determine the blood biomarker level at any time t
after a mTBI (Eq. 3). Based on published values of Tmax
and half-life, Azizi et al. estimated ka and ke using Eqs. 1
and 2 [74]. Estimates for ka and ke are shown in Table 2.
Kinetic modeling allows an estimate of Cp (the biomarker
blood level at time t) if estimates are available for amount
of biomarker released (D0 ), the fractional absorption rate
(F), and the volume of distribution (Vd ) as illustrated in
Fig. 3. (For details of the model see [74]).
t1 =
2

Tmax

0.693
ke
 
ln kkae
=
ka − ke

(1)

(2)
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Fig. 2 Tmax is the time at which the biomarker is at its highest level. The half-life is the time needed for the biomarker level to drop by 50% during
the elimination phase. Accurate estimates of half-life can only be made after the absorption phase is complete. With delayed or continuing
absorption of biomarker after mTBI estimates of half-life are difficult



F ∗ D0 ∗ ka
(3)
Cp =
∗ e−ke t − e−ka t
Vd ∗ (ka − ke )
Azizi et al. [74] have suggested that the amount of
biomarker released at impact (D0 ) could serve as a more
reliable marker for TBI severity than an isolated blood
biomarker level (Cp ) at a random time t. McDonald et al.
[13] have emphasized that whether biomarker is released
all-at-once at impact or is released in a delayed or continuing manner after mTBI is another known unknown.
The delayed release of biomarker can be modeled in a

one-compartment kinetic model by increasing Tmax and
decreasing the absorption rate constant (ka ) while keeping the amount of biomarker released constant (D0 ) [74].
Furthermore, differing kinetic curves for each biomarker
(Fig. 3) have implications for selecting the preferred sampling time for each biomarker.
What is the optimal timing for blood biomarker sampling?

For some neurological diseases such as fronto-temporal
dementia, Alzheimer disease, and multiple sclerosis,
blood sample timing for biomarkers is unlikely to be

Table 2 Kinetic parameters of commonly investigated biomarkers for mTBI
Biomarker

Normal Plasma

Normal CSF

Half-life

level (pg/ml)

level (pg/ml)

hrs∗

hrs∗

GFAP

60-70

2100

36

NF-L

6-20

400-1100

S100B

50-60

1800

tau

1-5

UCH-L1

8-10

∗

ka ‡

ke ‡

References

24

0.080

0.019

[9, 11, 12, 17, 65]

500??

100-300??

0.009

0.001

[8, 12, 67, 68]

1.5†

2

0.500

0.462

[9, 11, 27, 28, 65, 69, 70]

270

10

8

0.070

0.069

[8, 11, 71, 72]

4500

8

8

0.090

0.086

[9, 11, 17, 22, 65, 73]

Tmax

Values for half-life and Tmax are mid-range of reported estimates
S100B undergoes rapid redistribution to other compartments before renal elimination
Estimates are uncertain
‡
Estimates for the absorption constant (ka ) and elimination constant (ke ) compartment pharmacokinetic model with first order kinetics from [74].
†

??
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Fig. 3 Calculated time-concentration curves for four blood biomarkers after mTBI based on a one-compartment pharmacokinetic model [74]. Each
curve reflects a subject from the CARE dataset [31] who sustained a sports related concussion. Four blood biomarker levels were used to estimate
the amount of biomarker released at impact and the pharmacokinetic model was used to generate the time-concentration curve based on
Equation 3. Tests of modality suggested that biomarker levels were bi-modal [29]. Reproduced from [74] with permission

critical [75–77]. With mTBI, like stroke [78], the timing
of sampling is important. If blood biomarkers are sampled too early or too late compared to the Tmax , important
elevations may be missed. Based on their approximate
Tmax (Table 2), it is predicted that S100B is best sampled between 0-4 hrs, UCH-L1 and tau between 4-12 hrs,
GFAP between 12-36 hrs, and NF-L between 100-300 hrs.
Estimates for the Tmax of NF-L are not reliable and the
actual value of the Tmax could be much longer [12, 68].
Bogoslovsky et al. [10] have emphasized “intended context of use” for blood biomarkers and comment that blood

sample times often depend upon the clinical setting (playing field, ED, hospital ward, or rehabilitation center) or the
intended use (diagnosis of concussion, decisions around
return to sport, or decisions around CT scanning).
Empirical studies are needed to confirm the best sampling times for blood biomarkers after mTBI depending
on the intended context of use. In general, the best test
performance, as measured by AUROC (area under the
receiver operator curve), for S100B, UCH-L1, and tau
occurs with early sampling times of 0-6 hrs (Table 3).
Note that with the comparison of AUROCs across studies,
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Table 3 Performance at different sampling times for studies with multiple sampling intervals (Area under receiver operator curve)†
Biomarker

GFAP

NF-L

S100B

tau-T

UCH-L1

Study

Year

Use

Asken [79]

2018

concussion

0-1

0-6

6-24

0.63

0.71

24-48

McCrea [31]

2020

concussion

0.68

0.57

Meier [80]

2017

concussion

0.53

0.56

Papa [17]

2019

concussion

Posti [81]

2017

concussion

0.76

0.76

0.8

0.87

0.63

0.37

Yue [82]

2019

CT-/MRI+

0.72

0.85

Welch [65]

2017

CT+/CT-

0.84

0.94
0.60

48-144

>144

0.89

McDonald [68]

2021

concussion

Giza [83]

2021

concussion

0.75

McCrea [31]

2020

concussion

0.56

0.49

Shahim [84]

2017

PCS

0.82

0.73

Shahim [72]

2018

RTS

0.82

0.72

0.73

0.73

McDonald [68]

2021

concussion

0.73

0.85

0.79

Giza [83]

2021

concussion

0.75

Asken [79]

2018

concussion

0.75

Meier [80]

2017

concussion

0.72

Welch [65]

2017

CT+/CT-

0.78

Shahim [85]

2014

PCS

0.68

Rogatzki [86]

2021

concussion

Asken [79]

2018

concussion

0.74

McCrea [31]

2020

concussion

0.55

Shahim [85]

2014

PCS

0.90

0.48

0.52

0.54

0.83

0.66

0.63

0.63
0.69
0.58
0.75
0.55

0.24
0.62
0.31
0.76

Gill [87]

2017

RTS

0.80

Shahim [72]

2018

RTS

0.67

0.57

0.52

McDonald [68]

2021

concussion

0.51

0.55

Giza [83]

2021

concussion

0.50

0.46

Asken [79]

2018

concussion

0.62

McCrea [31]

2020

concussion

0.66

Meier [80]

2017

concussion

Papa [17]

2019

concussion

Posti [81]

2017

concussion

McDonald [68]

2021

concussion

Giza [83]

2021

concussion

0.74

0.60
0.51

0.74
0.65

0.55

0.65

0.77

0.52

0.46

0.73

0.72

0.74

0.50

0.61

0.56

0.57

0.62

∗

Use: concussion versus controls, mTBI with CT+ versus CT-, delayed return to sport versus no delay, CT- and MRI+ versus CT- and MRI-, post-concussion syndrome versus no
post-concussion syndrome.
†
Time intervals are in hours and are approximate across studies.
Bolded AUROC is the highest row value.
Values are rounded to 2 decimals. No tests of significance were applied.

there are no absolute standards for using the AUROC to
evaluate the predictive capacity of a diagnostic test. An
AUROC of 0.80 or greater generally suggests that the test
is clinically useful [88]. Unlike specificity and sensitivity,
AUROC provides a measure of test power that does not
depend upon selecting a specific cutpoint [88]. Few studies have examined whether it is possible to sample blood

too early after a mTBI. Even rapidly absorbed biomarkers,
such as S100B, take a measurable amount of time to be
released from injured neural elements, traverse the interstitial fluid, and cross the blood brain barrier or enter
drainage pathways to the blood. On the other hand, the
fall-off in levels with later sampling times is likely more
pronounced for S100B than with UCH-L1 or tau. Due to
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its rapid clearance from the blood, sampling times after 6
hrs are likely to miss important elevations of S100B after
mTBI. With the longer half-life of NF-L, a later sampling
time can yield a good AUROC. It is unclear if there is a
penalty for sampling NF-L too early after a mTBI (Table 3).
GFAP, which has a longer half-life than UCH-L1, S100B,
or tau, may be better sampled later than the 0-6 hr time
frame. For example, Welch et al. [65] found that GFAP
as a predictor of CT positivity performed better when
drawn at 12-18 hrs instead of 0-6 hrs. More investigation
is needed to set the optimal sampling time for each blood
biomarker for mTBI.
What are the confounding factors for blood biomarker
levels after mTBI?

One confounding factor for biomarker blood levels is total
blood volume (TBV). Individuals with higher blood volumes have lower blood biomarker levels. Manouchehrinia
et al. [89] studied NF-L levels in 2,586 multiple sclerosis patients and 662 controls. Mean NF-L levels were 7.52
pg/ml in the controls and 11.68 pg/ml in the multiple sclerosis cases. Plasma NF-L levels dropped by -0.15 pg/ml for
each liter of TBV in controls and -0.17 pg/ml per liter of
TBV in multiple sclerosis patients.
Another confounding factor is renal function. Since
some elimination of blood biomarker is likely renal,
impaired renal function can lengthen biomarker half-life
in the blood and elevate biomarker blood levels. Akamine
et al. [90] investigated the relationships between blood
NF-L levels and renal function in 43 healthy adults and
188 patients with diabetes mellitus. Blood neurofilament
levels correlated significantly with creatinine levels in
healthy controls (r=+0.50) and diabetic subjects (r=+0.56).
Endogenous levels of plasma neurofilament protein, tau,
and GFAP are known to rise with age [91–93]. In the
TRACK-TBI study, Gardner et al. [94] found that the
ability of GFAP to discriminate between CT+ and CTsubjects was less in the older age group (AUROC=0.73)
than the middle age (AUROC=0.92) or young age group
(AUROC=0.93). This age-related effect was not noted
with tau. Ward et al. [95] retrospectively examined
sensitivity and specificity of the Banyan Brain Trauma
Indicator (a tandem GFAP and UCH-L1 assay). They
found that while sensitivity was 100% in the ≥65 and
<65 age groups, specificity dropped from 0.44 to 0.13
in the older age group. They attributed this drop in
specificity to higher levels of GFAP and UCH-L1 in
the older CT- subjects. Levels of GFAP and UCH-L1
were not significantly higher by age in the CT+ subjects.
Iverson et al. [96] found both older patients with uncomplicated mTBI and orthopedic controls had higher NF-L
levels when blood was drawn within 19 hours of injury.
Calcagnile et al. [97] found higher levels of S100B in
older patients with mTBI and found that the specificity
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of the test to identify CT+ patients was reduced in the
elderly.
How long do blood biomarker levels remain elevated after
mTBI?

A few studies have examined biomarker levels months
or years after mTBI. Blood half-lives of most biomarkers (UCH-L1, S100B, GFAP) are short (less than 48 hrs)
[12]. With the exception of NF-L which has a longer halflife, biomarker levels at 30 to 90 days are expected to be
normal unless there is ongoing neural degeneration or reinjury . Shahim et al. [98] followed 89 subjects with mTBI
for up to five years. In some subjects, they found elevated
NF-L levels up to 5 years after mTBI. Levels of GFAP were
elevated for up to 30 days after mTBI. Tau and UCHL1 were at baseline levels after 30 days [98]. Shahim et
al. [99] found elevated NF-L levels in the cerebrospinal
fluid of professional hockey players with post-concussion
syndrome for up to one year after mTBI. Pattinson et al.
[100] studied 109 military personnel with a past history of
traumatic brain injury. They found TBI subjects did not
differ from controls in levels of tau, NF-L, Aβ40, or Aβ42.
McDonald et al. [68] found elevated blood NF-L levels for
up to 13 days after concussion in Australian football players and these levels discriminated concussed players from
control players. Bogoslovsky et al. [101] measured levels
of amyloid-β42, tau, and GFAP at 0, 30, and 90 days after
TBI in 34 subjects entered into the COBRIT trial. Subjects
were of mixed TBI severity; none had simple concussions.
They found elevated levels of three biomarkers compared to controls, although levels of tau and GFAP were
dropping. Currently, explanation for persistently elevated
biomarker levels after mTBI in some subjects remains
uncertain. Persistent elevations of NF-L after mTBI could
reflect ongoing release of biomarker from original injury
or re-injury [13]. The prognostic significance of these late
elevations is uncertain. Upregulation of protein synthesis
in some patients after TBI has been reported [102].
Can blood biomarkers diagnose concussive or
sub-concussive hits to the head?

Studies have shown that blood biomarkers have a modest
capability to distinguish healthy controls from concussed
subjects (Table 4). Most of the areas under the receiver
operator curves (AUROC) are below 0.80, suggesting only
fair discrimination between healthy controls and concussed subjects. Papa et al. [17] found higher levels of
UCH-L1 (AUROC =0.65) and GFAP (AUROC= 0.76) in
concussed head injury subjects compared to head injury
controls without concussion symptoms at 0 to 4 hrs. In the
0 to 6 hr time frame, McCrea et al. [31] found only modest
values for the AUROC for UCH-L1 (0.66), tau (0.55), NFL (0.56), and GFAP (0.68). One explanation for these low
AUROC levels may be that the response to a concussion
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Table 4 Area under the receiver operator curve (AUROC) for diagnosis of concussion per biomarker
Marker

Study

Year

Lead Author

GFAP

NF-L

S100B

tau-T

UCH-L1

∗
†
‡

Study Size

Sampling

(N)

Time (hrs)†

AUROC∗

Gill [71]

2018

277

0-48

0.93

Papa [17]

2019

452

0-4

0.76

Giza [83]

2021

167

0-6

0.75

Lewis [103]

2017

188

0-6

0.70

McCrea [31]

2020

206

0-6

0.68

Posti [81]

2017

44

0-24

0.63

Asken [79]

2018

29

0-4

0.63

McDonald [68]

2021

28

2 days

0.60

Meier [80]

2017

32

0-6

0.53

McDonald [68]

2021

20‡

6 days

0.85

Gill [71]

2018

277

0-48

0.77

Giza [83]

2021

167

0-6

0.73

McCrea [31]

2020

206

0-6

0.56

Wallace [104]

2018

12

6 days

NS

Asken [79]

2018

29

0-4

0.75

Meier [80]

2017

32

0-6

0.72

Lewis [103]

2017

188

0-6

0.69

Shahim [85]

2014

35

0-1

0.67

Rogatzi [86]

2021

8

0-1

0.48

Shahim [85]

2014

35

0-1

0.86

Asken [79]

2018

27

0-4

0.74

McDonald [68]

2021

20‡

13 days

0.72

Gill [71]

2018

277

0-48

0.68

McCrea [31]

2020

206

0-6

0.55

Giza [83]

2021

167

0-6

0.50

Wallace [104]

2018

11

6 days

NS

Wallace [104]

2019

11

14 days

NS

Meier [80]

2017

32

0-6

0.74

Giza [83]

2021

167

0-6

0.73

McCrea [31]

2020

206

0-6

0.66

Lewis [103]

2017

188

0-6

0.65

Papa [17]

2019

452

0-4

0.65

Asken [79]

2018

26

0-4

0.62

McDonald [68]

2021

20‡

2 days

0.61

Posti [81]

2017

44

0-24

0.52

The bolded AUROC value are ≥ 0.80.
Times are in hours except where noted.
Concussed male football players only, NS for 8 females

is bi-modal, with most subjects showing a modest rise in
blood biomarker levels and a smaller subset showing a
more robust rise in biomarker levels. Bui et al. [29] in their
review of data from the CARE mTBI dataset [30, 31] that
biomarker levels may be bimodal after mTBI, with only

a minority of concussed subjects exhibiting large rises in
biomarker levels.
Some studies have shown that sub-concussive hits to the
head can elevate biomarker levels. For example, Kawata
et al. [105] studied S100B levels before and after college
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football practices. None of the subjects sustained a concussion. They compared high-impact to low-impact subjects. Subjects with more hits and hits with higher peak
linear and rotational accelerations showed higher levels
of S100B. This pattern continued over multiple practices.
However, there was no cumulative effect on S100B levels over the season. On the other hand, Hulbregtse et al.
[2020], in a controlled randomized trial, compared soccer players who headed or kicked a soccer ball, found no
rise in plasma S100B levels at 0, 2, or 24 hrs after 10
headers. Puvenna et al. [14] found that the number of
sub-concussive hits during a varsity college football game
correlated with S100B levels but not UCH-L1 levels. Over
the course of a football season, sub-concussive hits to the
head caused no persistent increase in blood tau biomarker
levels [106].
Are blood biomarkers predictive of CT scan positivity after
mTBI?

Concussed patients with abnormalities on either MRI
or CT scan are termed complicated mTBI [107]. In the
CENTER-TBI project, 42.3% of 2955 subjects with mTBI
were classified as complicated mTBI. One goal of blood
biomarker research has been to discriminate between
patients with abnormalities on CT scan (CT positive)
from subjects without CT scan abnormalities (CT negative). The intent is to identify mTBI patients who are
unlikely to benefit from CT scanning. In general, the
biomarkers S100B and GFAP have shown a moderate ability to discriminate between CT-positive and CT-negative
subjects (Table 5).
Cost savings are possible if patients with mild head
injuries who are unlikely to benefit from CT scanning are
excluded from neuroimaging. In Europe, S100B has been
extensively studied as a biomarker that could reduce the
use of CT scanning for minor head injuries [26, 114]. If
a cutpoint of 100 pg/ml is used for S100B within 6 hrs
of head injury, the test is 97% sensitive and 34% specific
in predicting subjects with CT scan abnormalities [26].
A risk occurs with S100B due to its short half-life of 1-2
hrs [26], making false-negative tests possible if blood sampling is delayed excessively. However, false-negative tests
with S100B have only rarely been reported, and the biggest
problem in the use of the test has been low specificity. The
most recent validation of the Scandinavian Head Injury
Guideline with a cutoff of 100 pg/ml of S100B within 6
hrs of mild head injury showed a sensitivity of 0.94 and a
specificity of 0.19 in predicting abnormalities on CT scan.
The lower specificity has been attributed to the greater age
of the study group, with older patients having higher baseline levels of S100B [115]. If fully applied, the Scandinavian
Guidelines with S100B testing would have reduced CT
scanning by 9% [115]. Jones et al. [111] evaluated the predictive value of S100B for CT abnormalities in 679 mTBI
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subjects. Blood was drawn within 6 hours of head injury.
With a cutoff of 100 pg/ml, they found a sensitivity of 0.85,
a specificity of 0.34, a positive predictive value of 0.72, and
a negative predictive value of 0.97 for abnormalities on
the CT scan after mTBI. Calcagnile et al. [116] measured
S100B blood levels within 3 hours of injury in 726 subjects with mTBI. Using a cutoff of 100 pg/ml, they found
no subjects with a positive CT scan in the 229 subjects
with S100B below the cutoff point and found a positive
CT scan in 150 of the 497 subjects with an S100B over the
cutoff point. Another study found an S100B level above
100 pg/ml within 6 hours of injury predictive of CT scan
abnormalities [112]. In a meta-analysis of eight published
studies, Oris et al. [117] found a pooled sensitivity of 100%
and a pooled specificity of 35% when S100B levels were
obtained within 3 hrs of injury. Cutoff values for S100B
varied by study between 6 and 200 pg/ml. Ananthaharan
et al. [118] monitored the use of the S100B Scandinavian
CT scanning guidelines in mTBI. In 69 subjects with a
mTBI and S100B level below the cutoff of 100 pg/ml, all
had a negative CT scan.
In the United States, the FDA has approved the Banyan
BTI™(Brain Trauma Indicator) to predict CT scan abnormalities after mTBI. Blood is sampled within 12 hrs of
head injury. Test sensitivity is 97.5% and specificity is
36.5% on the FDA application [119]. The FDA has recently
approved a handheld testing platform for GFAP and
UCH-L1 levels with results available within 15 mins [120].
Okonkwo et al. [121] have reported on the point of care
testing of 1359 traumatic brain injury subjects of all severity levels. The AUROC for prediction of a positive CT scan
for GFAP (0.85) was significantly higher than S100B (0.67)
for subjects evaluated within 24 hr of injury.
Gill et al. [71] studied 277 subjects with suspected mTBI
in the emergency room setting. Levels of UCH-L1, NF-L,
tau, and GFAP were measured by single-molecule array
assay. By AUROC, GFAP outperformed tau and NF-L
in predicting neuroimaging abnormalities (CT or MRI).
Another study, done with the less sensitive ELISA assay,
suggested that GFAP was a better predictor of CT scan
abnormalities than S100B [122]. The TRACK-TBI study
evaluated 450 mTBI subjects who were CT scan negative.
GFAP levels were higher in MRI positive mTBI subjects
than MRI negative subjects. Both groups of mTBI were
significantly higher than orthopedic controls or healthy
controls [82]. Another study confirmed the ability of
GFAP to discriminate between CT positive and CT negative subjects with mTBI [109]. Lewis et al. [103] evaluated the ability of GFAP, UCH-L1, and S100B to stratify
247 emergency room patients who had biomarker levels
within 6 hrs of injury. All three biomarkers were higher
in subjects with complicated mTBI than mTBI and higher
in mTBI than no TBI. A cutoff of 30 pg/ml for GFAP,
30 pg/ml for UCH-L1, and 35 pg/ml for S100B gave a
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Table 5 Area under the receiver operator curve (AUROC) for CT positivity by biomarker
Marker

Study

Year

Lead Author

GFAP

NF-L

S100B

tau-P
tau-T

UCH-L1

Study Size

Sampling

(N)

Time (hrs)

AUROC

Czeiter [108]

2020

2867‡

0-24

0.89

Gardner [94]

2018

169

0-24

0.88

Huebschmann [109]

2020

121

0-12

0.81

Welch [65]

2016

251

0-6

0.78

Gill [71]

2018

277

0-48

0.77

Yue [82]∗

2019

450

0-24

0.77

Lewis [103]

2017

188

0-6

0.66

Gill [71]

2018

277

0-48

0.65

Welch [65]

2016

251

0-6

0.75

Allouchery [110]

2018

1449

0-2

0.72

Jones [111]

2020

679

0-6

0.69

Egea-Guerrero [112]

2018

260

0-6

0.67

Lewis [103]

2017

188

0-6

0.65

Yue [82]∗

2019

450

0-24

0.56

Gardner [94]

2018

169

0-24

0.93

Gardner [94]

2018

169

0-24

0.71

Diaz-Arrastia [113]

2014

171

0-24

0.67

Gill [71]

2018

277

0-48

0.66

Welch [65]

2016

251

0-6

0.79

Lewis [103]

2017

188

0-6

0.60

Yue [82]∗

2019

450

0-24

0.59

The bolded AUROC values are ≥ 0.80
This study compared MR- vs. MRI+ in CT- subjects. All other studies are CT- vs. CT+.
†
1951 of 2867 subjects had mTBI.
‡
Concussed male football players only, females excluded.
∗

sensitivity of 44% for GFAP, 95% for UCH-L1, and 96%
for S100B in distinguishing between no TBI and mTBI.
Cutoffs for distinguishing between complicated mTBI and
mTBI were not provided.
Are blood biomarkers predictive of severity and outcome
after mTBI?

Several clinical measures have been used to assess the
clinical severity of mTBI including the SAC (Standardized
Assessment of Concussion), the SCAT (Sports Concussion Assessment Tool), the BESS (Balance Error Scoring
System), BSI-18 (Brief Symptom Inventory-18), and the
ImPACT (Immediate Post-Concussion Assessment and
Cognitive Test (ImPACT). In general, few correlations
have been found between these clinical measures and
blood biomarker levels after mild TBI [29, 31, 68, 79, 83].
Giza et al. [83] found a weak correlation (r= 0.36) between
acute GFAP levels and the BESS. Bui et al. [29] examined clustering of biomarker trajectories for tau, UCH-L1,
GFAP, and NF-L. In general biomarker trajectory did not
predict TBI severity with three exceptions: clusters with

higher trajectories of NF-L and GFAP did worse on the
SAC at 6 hrs post mTBI, and a cluster with higher UCHL1 did worse on the verbal memory test at 7 days after
post return to sport. Nonetheless, the limited capacity
of blood biomarkers to correlate with mTBI severity has
been disappointing to date.
The prediction of outcome after mTBI has been difficult, whether the outcome is measured by the time
to recovery, the persistence of symptoms, or the development of a post-concussion syndrome (PCS). Accurate
models to predict outcome from mTBI are not available [123]. As assessed by AUROC, blood biomarkers are
weakly predictive of outcome after mTBI (Table 6). Both
NF-L and tau have shown a limited predictive ability for
return to sport in professional hockey players after concussion [67, 72, 84, 85]. NF-L levels measured up to 144
hours after injury and tau measured up to 12 hours after
injury were predictive of return to sport [71, 72, 85]. A
small study did not find cleaved tau levels predictive of
post-concussion syndrome [127]. Gill et al. [87] found
higher tau levels in student athletes with a prolonged

Hier et al. Biomarker Research

(2021) 9:70

Page 12 of 17

Table 6 Area under the receiver operator curve (AUROC) for biomarker studies predicting outcome from mTBI
Marker

Study

Year

N

Time (hrs)

AUROC

Outcome
Predicted

GFAP

NF-L

S100B

Huebschmann [109]

2020

121

0-12

0.69

GOS-E >6

Pattinson [124]

2020

59

0-12

0.40

RTS <8 days

Shahim [72]

2018

87

0-1

0.83

RTS <15 days

Shahim [84]

2017

35

0-1

0.82

RTS <6 days

Shahim [85]

2014

28

0-1

0.68

Duration of PCS <6 days

Babcock [125]

2008

76

0-6

0.47

Onset of PCS

tau-A

Shahim [67]

2016

28

0-1

0.87

RTS <10 days

tau-C

Shahim [67]

2016

28

0-1

0.58

RTS <10 days

tau-T

Shahim [85]

2014

28

0-1

0.91

Duration of PCS <6 days

Gill [87]

2017

43

0-6

0.81

RTS <10 days

Pattinson [124]

2020

59

Recovered

0.75

RTS <8 days

Shahim [72]

2018

87

0-1

0.67

RTS <15 days

Pattinson [124]

2020

55

24-48

0.66

RTS <8 days

Hossain [126]

2020

105

0-24

0.56

GOS-E > 7

RTS Return to sport.
bolded AUROC values ≥ 0.80

return to sport after sports-related concussion. In a larger
study, Pattinson et al. [124] studied 127 concussed student athletes and found that early tau levels were weakly
predictive of return to sport. Similarly, Hossain et al.
[126] found a weak correlation between admission tau levels and Glasgow Outcome Scale-Extended score at 6-12
months.

Conclusions
This review examined eight unresolved issues related to
the use of blood biomarkers for the diagnosis and management of mTBI. A number of review limitations should
be emphasized. We focused on the five most commonly
investigated blood biomarkers after mTBI and did not
address other blood biomarkers such as neuron specific enolase (NSE), myelin basic protein, inflammatory
biomarkers, or microRNA [128]. Our review methodology was a focused and not systematic. We have used the
more general term blood biomarker level and have not
distinguished between plasma and serum levels (although
plasma and serum levels differ, they are generally highly
correlated [129]). Analytic issues such as test-retest reliability, test sensitivity, inconsistencies across test platforms,
and issues related to storage and handling of samples have
not been addressed in this work (for a discussion of some
of these issues see [13]. We focused on blood levels of
biomarkers and did not address biomarker levels in the
cerebrospinal fluid, urine, or saliva [130, 131].
Evidence from the clinical setting and from animal models indicates a disruption of the blood brain barrier occurs

after moderate to severe traumatic brain injury [132–136,
136–139] and that biomarkers can cross the blood brain
barrier into the blood [11, 62]. In mTBI, the blood brain
barrier may be disrupted as well [132, 137]. Nonetheless,
a disruption of the blood brain barrier may not be essential for the entry of biomarkers into the blood. Opinion
is growing that protein biomarkers enter the blood by
alternate routes [15] including the intramural periarterial
drainage system and the glymphatic system. The route of
entry by biomarkers, whether by crossing the blood brain
barrier, through glymphatics, or via other drainage pathways, likely influences the rate of absorption and kinetics
of blood biomarkers for mTBI.
Kinetic parameters such as Tmax and half-life provide important information about the behavior of mTBI
biomarkers in the blood. Current estimates of these
kinetic parameters are imprecise [13]. Better estimates
of kinetic parameters would allow more precise modeling of biomarker levels after TBI and foster more precise
cutoff levels and sampling times. Available evidence suggests that the optimal sampling time for S100B after
mTBI is between 1 and 3 hours, for tau and UCH-L1
optimal sampling time is likely between 2 and 8 hours.
The optimal sampling time for GFAP is likely later, possibly between 6 and 18 hours. There is less certainty
about the optimal sampling time for NF-L due to uncertainty about biomarker half-live and Tmax , but it is likely
later than the other commonly measured biomarkers for
mTBI. Several confounding factors for blood biomarker
levels have been identified including increasing age, renal
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failure, and increased blood volume. However, corrections
in biomarker levels are not routinely made for these confounding factors. Elevated levels of both tau and NF-L
have been observed months or years after traumatic brain
injury. The significance of these persistent elevations in
blood biomarker levels is uncertain.
Blood biomarkers have a modest ability to detect subconcussive head injuries and a modest ability to discriminate between concussed and non-concussed subjects.
Some subjects with verified concussions may have minimal increases in blood biomarker levels which overlap
with the levels found in control subjects. None of the
studied blood biomarkers have been shown to reliably correlate with repetitive sub-concussive hits or cumulative
concussive hits to the head. Blood biomarkers have had
some success in predicting CT scan positivity after mild
traumatic brain injury. S100B is widely used in Europe,
and the GFAP/UCH-L1 tandem test has been approved
for use in the United States. Despite impressive levels of
sensitivity, these tests lack high levels of specificity. Correlations between blood biomarker levels and mTBI severity
have been disappointing to date. Evidence is inconclusive as to whether any blood biomarker predicts recovery
time, post-concussion syndrome, or return to sport after
mild traumatic brain injury. Both tau and neurofilament
light chain protein have shown limited promise for this
application. Return to sport and return to work decisions
are influenced by complex educational, sociological, and
psychological factors not captured in a blood biomarker
test [140].
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